ABC Arbitrage SA Buys Shares of 19,244 Valneva SE (NASDAQ:VALN)

ABC Arbitrage SA acquired a new position in Valneva SE (NASDAQ:VALN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 19,244 shares of the company’s stock, valued at approximately $84,000.

Separately, AlphaCentric Advisors LLC grew its position in shares of Valneva by 33.7% in the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock worth $717,000 after buying an additional 29,748 shares during the last quarter. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Stock Down 14.4 %

NASDAQ:VALN opened at $6.67 on Friday. The company has a market cap of $542.00 million, a PE ratio of -51.31 and a beta of 1.98. Valneva SE has a twelve month low of $3.62 and a twelve month high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company’s 50 day moving average is $4.92 and its two-hundred day moving average is $5.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Valneva in a research report on Friday, January 31st.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.